↓ Skip to main content

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity

Overview of attention for article published in Brain, July 2010
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news
2 news outlets
blogs
1 blog
policy
2 policy sources
patent
3 patents

Citations

dimensions_citation
149 Dimensions

Readers on

mendeley
191 Mendeley
connotea
1 Connotea
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity
Published in
Brain, July 2010
DOI 10.1093/brain/awq176
Pubmed ID
Authors

Joanne L. Jones, Jane M. Anderson, Chia-Ling Phuah, Edward J. Fox, Krzysztof Selmaj, David Margolin, Stephen L. Lake, Jeffrey Palmer, Sara J. Thompson, Alastair Wilkins, Daniel J. Webber, D. Alastair Compston, Alasdair J. Coles

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 191 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 2%
Germany 2 1%
Spain 2 1%
Argentina 1 <1%
Netherlands 1 <1%
United Kingdom 1 <1%
Belgium 1 <1%
Unknown 180 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 41 21%
Student > Bachelor 26 14%
Student > Master 21 11%
Student > Ph. D. Student 20 10%
Other 16 8%
Other 40 21%
Unknown 27 14%
Readers by discipline Count As %
Medicine and Dentistry 78 41%
Agricultural and Biological Sciences 26 14%
Neuroscience 15 8%
Biochemistry, Genetics and Molecular Biology 10 5%
Pharmacology, Toxicology and Pharmaceutical Science 6 3%
Other 20 10%
Unknown 36 19%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 33. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 February 2022.
All research outputs
#1,211,613
of 25,373,627 outputs
Outputs from Brain
#1,276
of 7,626 outputs
Outputs of similar age
#3,660
of 104,616 outputs
Outputs of similar age from Brain
#6
of 63 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,626 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 27.7. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 104,616 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 63 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.